TNGN News Alert Tengion (TNGN) 0.0590 09/20/2014 05:57:31

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tengion (TNGN) 0.0590 $TNGN

Arizona State University Lauded for Entrepreneurship, Economic Growth
PRWeb - Thu Aug 21, 7:07AM CDT
Arizona State University is among 12 universities recognized for their accomplishments "as creators of intellectual capital and economic growth" in a recent book-length report on the nexus between university innovation and economic development.

Tengion Provides Clinical Update and Reports Second Quarter 2014 Financial Results
GlobeNewswire - Wed Aug 13, 11:31AM CDT
Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported key clinical data along with financial and operating results for the quarter ended June 30, 2014.

Tengion Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Mar 26, 3:05PM CDT
Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2013 and provided a business update.

Tallwave Expands High Tide Lean Business Competition to Include Ed Tech and Healthcare IT From Across the Country and Adds Industry Agnostic "Wildcard" Slots for Arizona IT Startups
Marketwire - Thu Mar 13, 2:14PM CDT
Tallwave today announced it is opening applications in its latest High Tide(TM) competition to Healthcare IT entrepreneurs from across the country. These entrepreneurs will join peers applying for the program in the previously announced focus on innovations in Ed Tech. In addition, Tallwave has reserved four to six slots for Arizona-only IT companies regardless of the industry sector they hail from. The deadline for submission is March 31, 2014 and can be completed online at www.tallwavehightide.com.

Tengion to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 3:30PM CST
Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that John L. Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming 26th Annual ROTH Conference on Monday, March 10, 2014, at 12:30 p.m. PDT in Dana Point, CA.

Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
PR Newswire - Wed Aug 14, 3:05PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the second quarter ended June 30, 2013.

OTC Daily Alert Stock Watch - Tengion (OTCQB: TNGN)
WorldStockWire - Sat Aug 10, 7:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Tengion Announces Promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance
PR Newswire - Wed Aug 07, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance. Mr. Davis has served as Chief Financial Officer of Tengion since joining the Company in 2010 and recently helped facilitate the Company in raising $33.6M to fund research and development activities for its two lead clinical programs, the Neo-Kidney Augment(TM) and the Neo-Urinary Conduit(TM).

Market Maker Surveillance Report. OSTK, STXS, ZHNE, TNGN, GAME, HGSH, Winning Stocks With Lowest Price Friction For Thursday, July 18th 2013
M2 - Fri Jul 19, 2:05AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 3821 companies with "abnormal" market making, 3241 companies with positive Friction Factors and 1918 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Overstock.com Inc (NASDAQ:OSTK), Stereotaxis Inc (NASDAQ:STXS), Zhone Technologies Inc (NASDAQ:ZHNE), Tengion Inc (OTC:TNGN), Shanda Games Ltd (NASDAQ:GAME), China Hgs Real Estate Inc (NASDAQ:HGSH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Tengion Announces Transactions Totaling $33.6 Million to Advance its Organ Regeneration Platform(TM)
PR Newswire - Mon Jul 01, 1:41PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the closing of transactions totaling $33.6 million to fund its two lead clinical programs, the Neo-Kidney Augment(TM) and the Neo-Urinary Conduit(TM).

Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting
PR Newswire - Wed Jun 12, 3:30PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the International Society for Stem Cell Research (ISSCR) 11th Annual Meeting being held June 12th-15th, 2013 in Boston, Massachusetts.

Tengion Provides Business Update and Reports First Quarter 2013 Financial Results
PR Newswire - Wed May 15, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the first quarter ended March 31, 2013.

Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
PR Newswire - Mon Apr 01, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the acceptance of the Company's Clinical Trial Application (CTA) filed with the Medical Products Agency (MPA) in Sweden to initiate a Phase 1 clinical trial to evaluate the safety and delivery of its Neo-Kidney Augment(TM) product in up to five patients with advanced chronic kidney disease (CKD).

Tengion Provides Business Update and Reports Fourth Quarter and Full Year 2012 Financial Results
PR Newswire - Mon Mar 18, 6:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2012 and provided a business update.

Tengion to Present at 25th Annual ROTH Conference
PR Newswire - Tue Mar 12, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that John L. Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming 25th Annual ROTH Conference on Tuesday, March 19, 2013, at 2:00 p.m. PDT in Laguna Niguel, CA.

Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013
PR Newswire - Mon Mar 11, 3:00PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 18, 2013, at 9:00 a.m. EDT to provide a business update and discuss its fourth quarter and full year 2012 financial results.

Tengion to Present at the BIO CEO & Investor Conference
PR Newswire - Tue Feb 05, 7:00AM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that A. Brian Davis, Chief Financial Officer and Vice President, Finance of Tengion, will present at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:30 a.m. EST in New York City.

Tengion Announces Clinical Progress for Neo-Urinary Conduit(TM) Phase 1 Trial and Regulatory Advance for Neo-Kidney Augment(TM)
PR Newswire - Wed Jan 30, 3:30PM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced advances for its two lead programs, the Neo-Urinary Conduit(TM) and Neo-Kidney Augment(TM).

Tengion Announces Change to Board of Directors
PR Newswire - Fri Dec 21, 7:15AM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Scott D. Flora, President & Chief Executive Officer at OmniGuide, has resigned from Tengion's Board of Directors, effective December 19, 2012.

Regenerative Medicine - Global Strategic Business Report
M2 - Mon Dec 17, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/qhqtfr/regenerative) has announced the addition of the "Regenerative Medicine - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Regenerative Medicine in US$ million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 93 companies including many key and niche players such as: - BioVest International Inc. - Curis Inc. - Cytori Therapeutics Inc. - Evotec AG - Forticell Bioscience Inc. - Geron Corporation - Integra LifeSciences Corporation - LifeCell Corporation - Osiris Therapeutics Inc. - Tengion Inc. - Tepha Inc. - TiGenix N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public doma




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Neurotrope, Inc. Achieves New Milestone with Stock Surge

Updated Category News Views 147

Neurotrope, Inc. Reaches New Stock Milestone Neurotrope, Inc. (NASDAQ: NTRP) has recently achieved a significant milestone in the stock market, soaring to a 52-week high with its price reaching $7.00. This impressive climb indicates a remarkable 124.95% increase over the past year, showcasing strong investor interest and confidence in the company's future prospects. The...

Continue Reading
Lil Nas X's Legal Challenges and Public Struggles Unfold

Updated Category News Views 284

Lil Nas X Pleads Not Guilty to Serious Charges Grammy-winning musician Lil Nas X has recently made headlines for pleading not guilty to multiple felony charges stemming from an incident involving police officers. This situation arose when he was found walking unclothed on the streets of Los Angeles. Understanding the Legal Battle Ahead The rapper, known legally as Montero...

Continue Reading
Exyte's Strategic Acquisition of TTP Group Enhanced Operations

Updated Category News Views 51

Exyte Acquires TTP Group to Strengthen Engineering Expertise Exyte, a leader in high-tech facility engineering, has officially completed the acquisition of TTP Group, enhancing its operations and expertise especially in the biopharma and life sciences sectors. This acquisition marks a significant milestone for Exyte as it melds TTP's capabilities with its own, aiming to...

Continue Reading
Unveiling Health Innovations: Zepp Health at CES 2024 Events

Updated Category News Views 372

Zepp Health Showcases Innovative Technologies at CES Zepp Health Corporation (NYSE: ZEPP), a leader in health technology and smart wearables, is excited to announce its participation in significant media events like Pepcom and ShowStoppers at CES. These occasions will showcase Zepp Health's latest advancements in smart wearables and health technologies, aimed at...

Continue Reading
Meridian Locks $186M Loan for NJ Condo Project

Updated Category News Views 163

New Jersey's Coastline Gets a $186 Million Facelift Here's a move that'll shake the Jersey Shore awake: Meridian Capital Group's just put their money where the sand is with a massive $186 million scoop for a new high-end condominium project in Asbury Park. You couldn't make up a better setting—a beachfront spot ripe for some high-end living. But let's not get too...

Continue Reading